Clinical Trial Update: A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial of a CGRP monoclonal antibody for diabetic polyneuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Polyneuropathy

Drugs mentioned

• CGRP monoclonal antibody

Snippet

Sponsor: Mayo Clinic | Conditions: Diabetic Polyneuropathy | Phase 2 | Status: WITHDRAWN